Search

Your search keyword '"Kallweit U"' showing total 132 results
Start Over Author "Kallweit U"
132 results on '"Kallweit U"'

20. MRI in atypical idiopathic inflammatory demyelinating disease treated with methylprednisolone and cyclophosphamide

Author

Kallweit, U., Pohlau, D., Pauleit, D., and Harzheim, M.

Subjects
Methylprednisolone -- Dosage and administration -- Health aspects -- Usage, Guillain-Barre syndrome -- Drug therapy -- Diagnosis, Cyclophosphamide -- Dosage and administration -- Health aspects -- Usage, Magnetic resonance imaging -- Usage -- Health aspects, Health, Diagnosis, Drug therapy, Usage, Dosage and administration, Health aspects
Abstract

Byline: U. Kallweit, D. Pohlau, D. Pauleit, M. Harzheim The differential diagnosis of multi-focal enhancing lesions in cranial magnetic resonance imaging (MRI) is often difficult and includes a wide spectrum [...]

Published
2008

23. Insomnie - Diagnose und Therapie

Author

Kallweit, U, Nelles, L, University of Zurich, and Kallweit, U

Subjects
610 Medicine & health, 2700 General Medicine, 10040 Clinic for Neurology
Published
2010

28. Inter-hemispheric oscillations in human sleep

Author

Imbach, L L, Werth, E, Kallweit, U, Sarnthein, J, Scammell, T E, Baumann, C R, and University of Zurich

Subjects
1000 Multidisciplinary, 1300 General Biochemistry, Genetics and Molecular Biology, 610 Medicine & health, 1100 General Agricultural and Biological Sciences, 10040 Clinic for Neurology
Published
2012

33. CD4+ and CD8+ autoreactive T cells in narcolepsy patients target self-antigens of hypocretin-producing neurons

Author

Latorre, D, primary, Kallweit, U, additional, Armentani, E, additional, Foglierini, M, additional, Mele, F, additional, Cassotta, A, additional, Jovic, S, additional, Jarrossay, D, additional, Mathis, J, additional, Becher, B, additional, Lazavecchia, A, additional, Khatami, R, additional, Manconi, M, additional, Tafti, M, additional, Bassetti, CL, additional, and Sallusto, F, additional

Full Text
View/download PDF

36. Dopaminergic treatment in idiopathic restless legs syndrome: Effects on subjective sleepiness

Author

Claudio L. Bassetti, Fabio Pizza, Ulf Kallweit, Johannes Mathis, Ramin Khatami, Kallweit, U., Khatami, R., Pizza, F., Mathis, J., Bassetti, C.L., University of Zurich, and Kallweit, U

Subjects
Male, Time Factors, Excessive daytime sleepiness, Anxiety, Severity of Illness Index, law.invention, Levodopa, Benserazide, Pramipexole, Randomized controlled trial, law, Drug Combination, 2736 Pharmacology (medical), Pharmacology (medical), Restless legs syndrome, Aged, 80 and over, Cross-Over Studies, Depression, Epworth Sleepiness Scale, Cross-Over Studie, Middle Aged, Drug Combinations, 3004 Pharmacology, 2728 Neurology (clinical), Dopamine Agonists, Female, Sleep Stages, medicine.symptom, Psychology, medicine.drug, Human, Adult, medicine.medical_specialty, Time Factor, Sleep Stage, 610 Medicine & health, Disorders of Excessive Somnolence, Dopamine Agonist, Double-Blind Method, Internal medicine, Restless Legs Syndrome, Severity of illness, mental disorders, medicine, Humans, Benzothiazoles, Wakefulness, Aged, Pharmacology, Benzothiazole, medicine.disease, Crossover study, 10040 Clinic for Neurology, body regions, Physical therapy, Neurology (clinical), Body mass index
Abstract

Objectives: To assess frequency and characteristics of excessive daytime sleepiness (EDS) in restless legs syndrome (RLS) and the evolution of EDS under different RLS therapies. Methods: We analyzed data from the "Swiss RLS" study, which was conducted to compare treatment efficacy and safety of the dopamine agonist pramipexole (PPX) versus L-dopa/benserazide (LB) in de novo patients with idiopathic RLS and performed as a randomized, double-dummy, comparative crossover trial. Primary outcome measure of the present study was the change in subjective sleepiness (as measured by Epworth sleepiness scale [ESS] score). There were 37 patients (21 women) included. Mean age was 56.6 years (range, 25-85 years), and mean body mass index was 24.6 (SD, ±3.5). Results: At baseline, EDS (as determined by an ESS score of >10) was found in 32% of the patients. Sleepy RLS patients were younger (P < 0.001) than nonsleepy patients. Pramipexole and L/B both were effective in the treatment of RLS symptoms (IRLS score, P < 0.00 and P = 0.002). Overall, ESS was reduced (main effect for "time", P = 0.02) independent from the dopaminergic substance. In 5 of 37 7 patients, ESS score deteriorated to greater than 10 under treatment (PPX = 3 patients, L/B = 2 patients). No sleep attack occurred. Conclusions: Excessive daytime sleepiness is frequent in RLS patients. Dopaminergic treatment usually promotes wakefulness, but infrequently leads to daytime sleepiness.

Published
2010

37. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Author

[Weibel D, de Ridder M, Dodd C, Vanrolleghem A, Perez-Vilar S] Medical Informatics Department, Erasmus Medical Center, Rotterdam, The Netherlands. [Sturkenboom M] Julius Global Health, University Utrecht Medical Center, Utrecht, The Netherlands. [Black S] Cincinnati Children’s Hospital, Cincinnati, OH, USA. [Bonhoeffer J] Infectiology and Vaccinology University Children’s Hospital, Basel, Switzerland. Brighton Collaboration Foundation, Basel, Switzerland. [van der Maas N] Dept. Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Lammers GJ] Leiden University Medical Centre, Leiden, The Netherlands. Sleep-Wake Center SEIN, Heemstede, The Netherlands. [Overeem S] Sleep Medicine Centre Kempenhaeghe, Heeze, The Netherlands. [Gentile A, Giglio N, Castellano V] Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina. [Kwong JC, Cauch-Dudek K, Juhasz D, Campitelli M] Institute for Clinical Evaluative Sciences (ICES), Ontario, Canada. [Murray BJ] Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Canada. [Datta AN] University Hospital Basel, Basel, Switzerland. [Kallweit U] Bern University Hospital and University of Bern, Bern, Switzerland. Witten/Herdecke University, Department of Rehabilitation, Witten/Herdecke, Germany. [Huang WT] Taiwan Centers for Disease Control, Taipei, Taiwan. [Huang YS] Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital and University, Taoyuan, Taiwan. [Hsu CY] Department of Neurology and Sleep Disorders Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. [Chen HC] Department of Psychiatry and Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan. [Giner-Soriano M, Morros R] Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Barcelona, Spain. [Gaig C] Neurology Service and Multidisciplinary Sleep Disorders Unit, Hospital Clinic of Barcelona, Barcelona, Spain. [Tió E] Althaia Xarxa Assistencial Universitària de Manresa, Neurology Service, Manresa, Barcelona, Spain. [Perez-Vilar S, Diez-Domingo J] Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat (FISABIO), Vaccine Research, Valencia, Spain. [Puertas FJ] Servicio de Neurofisiologia, Hospital Universitari de la Ribera, Valencia, Spain. [Svenson LW] Division of Preventive Medicine, University of Alberta, Alberta, Canada. [Mahmud SM] Vaccine and Drug Evaluation Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada. [Carleton B] Faculty of Medicine, University of British Columbia, British Columbia, Canada. [Arnheim-Dahlström L] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [Pedersen L] Clinical Medicine/Epidemiology, Aarhus University, Aarhus, Denmark. [DeStefano F, Shimabukuro TT] Centers for Disease Control and Prevention (CDC), Immunization Safety Office, Atlanta, USA and IDIAP Jordi Gol

Subjects
Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Terapéutica::Terapia Biológica::Inmunomodulación::Inmunoterapia::Inmunización::Inmunoterapia Activa::Vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Adjuvants immunològics, Narcolèpsia, Grip A (H1N1) - Vacunació - Estudi de casos, Other subheadings::Other subheadings::/adverse effects [Other subheadings], Virus::Virus ARN::Orthomyxoviridae::Influenzavirus A::Virus de la Influenza A::Subtipo H1N1 del Virus de la Influenza A [ORGANISMOS], Enfermedades del Sistema Nervioso::Trastornos del Sueño-Vigilia::Disomnias::Trastornos Intrínsecos del Sueño::Trastornos de Somnolencia Excesiva::Narcolepsia [ENFERMEDADES], Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], Técnicas de Investigación::Métodos Epidemiológicos::Características de Estudios Epidemiológicos::Estudios Epidemiológicos::Estudios de Cohortes [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Nervous System Diseases::Sleep Wake Disorders::Dyssomnias::Sleep Disorders, Intrinsic::Disorders of Excessive Somnolence::Narcolepsy [DISEASES], Viruses::RNA Viruses::Orthomyxoviridae::Influenzavirus A::Influenza A virus::Influenza A Virus, H1N1 Subtype [ORGANISMS]
Published
2021

38. Awakening to sleep disorders in Europe: Survey on education, knowledge and treatment competence of European residents and neurologists

Author

Fabio Pizza, Hildegard Hidalgo, David R. Schreier, Martin Rakusa, Markus H. Schmidt, Mariusz Siemiński, Cristian Falup-Pecurariu, Elisa Baldin, Rolf Fronczek, Ulf Kallweit, Claudio L. Bassetti, Sofia Rakusa, Maria-Lucia Muntean, Valérie Cochen De Cock, Angelique Pijpers, Rakusa M., Sieminski M., Rakusa S., Falup-Pecurariu C., Fronczek R., Hidalgo H., Muntean M.-L., Pijpers A., Cochen De Cock V., Pizza F., Schmidt M., Schreier D.R., Baldin E., Bassetti C.L.A., and Kallweit U.

Subjects
Adult, Sleep Wake Disorders, medicine.medical_specialty, Neurology, residency programme, Population, Sleep medicine, Neurologist, Competence (law), Surveys and Questionnaires, medicine, Humans, Surveys and Questionnaire, clinical neurology, Neurologists, education, 610 Medicine & health, Curriculum, sleep disorder, education.field_of_study, business.industry, Neurology Residency, Internship and Residency, Mean age, Sleep in non-human animals, Europe, Family medicine, sleep disorders, Neurology (clinical), business, Human
Abstract

OBJECTIVES Sleep-wake disorders are common in the general population and in most neurological disorders but are often poorly recognized. With the hypothesis that neurologists do not get sufficient training during their residency, the Young European Sleep Neurologist Association (YESNA) of the European Academy of Neurology (EAN) performed a survey on postgraduate sleep education. METHODS A 16-item questionnaire was developed and distributed among neurologists and residents across European countries. Questions assessed demographic, training and learning preferences in sleep disorders, as well as a self-evaluation of knowledge based on five basic multiple-choice questions (MCQs) on sleep-wake disorders. RESULTS The questionnaire was completed by 568 participants from 20 European countries. The mean age of participants was 31.9 years (SD 7.4 years) and was composed mostly of residents (73%). Three-quarters of the participants reported undergraduate training in sleep medicine, while fewer than 60% did not receive any training on sleep disorders during their residencies. Almost half of the participants (45%) did not feel prepared to treat neurological patients with sleep problems. Only one-third of the participants correctly answered at least three MCQs. Notably, 80% of participants favoured more education on sleep-wake disorders during the neurology residency. CONCLUSIONS Education and knowledge on disorders in European neurological residents is generally insufficient, despite a strong interest in the topic. The results of our study may be useful for improving the European neurology curriculum and other postgraduate educational programmes.

Published
2021

39. Narcolepsy and adjuvanted pandemic influenza A (H1N1) 2009 vaccines – Multi-country assessment

Author

Weibel, Daniel, Sturkenboom, Miriam, Black, Steven, de Ridder, Maria A. J., Dodd, Caitlin, Bonhoeffer, Jan, Vanrolleghem, Ann, van der Maas, Nicoline, Lammers, Gert Jan, Overeem, Sebastiaan, Gentile, Angela, Giglio, Norberto, Castellano, Vanesa, Kwong, Jeffrey C., Murray, Brian J., Cauch-Dudek, Karen, Juhasz, Diana, Campitelli, Michael, Datta, Alexandre N., Kallweit, Ulf, Huang, Wan-Ting, Huang, Yu-Shu, Hsu, Chung-Yao, Chen, Hsi-Chung, Giner-Soriano, Maria, Morros, Rosa, Gaig, Carles, Tió, Ester, Perez-Vilar, Silvia, Diez-Domingo, Javier, Puertas, Francisco Javier, Svenson, Lawrence W., Mahmud, Salaheddin M., Carleton, Bruce, Naus, Monika, Arnheim-Dahlström, Lisen, Pedersen, Lars, DeStefano, Frank, Shimabukuro, Tom T., Universitat Autònoma de Barcelona, [Weibel D, de Ridder M, Dodd C, Vanrolleghem A, Perez-Vilar S] Medical Informatics Department, Erasmus Medical Center, Rotterdam, The Netherlands. [Sturkenboom M] Julius Global Health, University Utrecht Medical Center, Utrecht, The Netherlands. [Black S] Cincinnati Children’s Hospital, Cincinnati, OH, USA. [Bonhoeffer J] Infectiology and Vaccinology University Children’s Hospital, Basel, Switzerland. Brighton Collaboration Foundation, Basel, Switzerland. [van der Maas N] Dept. Epidemiology and Surveillance, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. [Lammers GJ] Leiden University Medical Centre, Leiden, The Netherlands. Sleep-Wake Center SEIN, Heemstede, The Netherlands. [Overeem S] Sleep Medicine Centre Kempenhaeghe, Heeze, The Netherlands. [Gentile A, Giglio N, Castellano V] Hospital de Niños Ricardo Gutiérrez, Ciudad Autónoma de Buenos Aires, Argentina. [Kwong JC, Cauch-Dudek K, Juhasz D, Campitelli M] Institute for Clinical Evaluative Sciences (ICES), Ontario, Canada. [Murray BJ] Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, University of Toronto, Canada. [Datta AN] University Hospital Basel, Basel, Switzerland. [Kallweit U] Bern University Hospital and University of Bern, Bern, Switzerland. Witten/Herdecke University, Department of Rehabilitation, Witten/Herdecke, Germany. [Huang WT] Taiwan Centers for Disease Control, Taipei, Taiwan. [Huang YS] Department of Child Psychiatry and Sleep Center, Chang Gung Memorial Hospital and University, Taoyuan, Taiwan. [Hsu CY] Department of Neurology and Sleep Disorders Center, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. [Chen HC] Department of Psychiatry and Center of Sleep Disorders, National Taiwan University Hospital, Taipei, Taiwan. [Giner-Soriano M, Morros R] Institut Universitari d’Investigació en Atenció Primària Jordi Gol (IDIAP Jordi Gol), Universitat Autònoma de Barcelona, Bellaterra (Cerdanyola del Vallès), Barcelona, Spain. [Gaig C] Neurology Service and Multidisciplinary Sleep Disorders Unit, Hospital Clinic of Barcelona, Barcelona, Spain. [Tió E] Althaia Xarxa Assistencial Universitària de Manresa, Neurology Service, Manresa, Barcelona, Spain. [Perez-Vilar S, Diez-Domingo J] Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat (FISABIO), Vaccine Research, Valencia, Spain. [Puertas FJ] Servicio de Neurofisiologia, Hospital Universitari de la Ribera, Valencia, Spain. [Svenson LW] Division of Preventive Medicine, University of Alberta, Alberta, Canada. [Mahmud SM] Vaccine and Drug Evaluation Centre, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Manitoba, Canada. [Carleton B] Faculty of Medicine, University of British Columbia, British Columbia, Canada. [Arnheim-Dahlström L] Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden. [Pedersen L] Clinical Medicine/Epidemiology, Aarhus University, Aarhus, Denmark. [DeStefano F, Shimabukuro TT] Centers for Disease Control and Prevention (CDC), Immunization Safety Office, Atlanta, USA, IDIAP Jordi Gol, Medical Informatics, Signal Processing Systems, Eindhoven MedTech Innovation Center, and Biomedical Diagnostics Lab

Subjects
Narcolepsy/immunology, MF59, Grip A (H1N1) - Vacunació - Estudi de casos, SDG 3 – Goede gezondheid en welzijn, Otros calificadores::Otros calificadores::/efectos adversos [Otros calificadores], AS03, Influenza Vaccines/therapeutic use, Nervous System Diseases::Sleep Wake Disorders::Dyssomnias::Sleep Disorders, Intrinsic::Disorders of Excessive Somnolence::Narcolepsy [DISEASES], 0302 clinical medicine, Influenza A Virus, H1N1 Subtype, Pandemic, Influenza, Human/immunology, Influenza A Virus, Pandemrix, Medicine, Enfermedades del Sistema Nervioso::Trastornos del Sueño-Vigilia::Disomnias::Trastornos Intrínsecos del Sueño::Trastornos de Somnolencia Excesiva::Narcolepsia [ENFERMEDADES], 030212 general & internal medicine, virus::virus ARN::Orthomyxoviridae::Influenzavirus A::virus de la gripe A::virus de la gripe A del subtipo H1N1 [ORGANISMOS], Adjuvant, Incidence (epidemiology), Vaccination, Human/immunology, Infectious Diseases, Influenza A Virus, H1N1 Subtype/immunology, Influenza Vaccines, Adjuvants immunològics, técnicas de investigación::métodos epidemiológicos::características de los estudios epidemiológicos::estudios epidemiológicos::estudios de cohortes [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Molecular Medicine, Public Health, Immunologic/therapeutic use, Terapéutica::Terapia Biológica::Inmunomodulación::Inmunoterapia::Inmunización::Inmunoterapia Activa::Vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Narcolèpsia, Virus::Virus ARN::Orthomyxoviridae::Influenzavirus A::Virus de la Influenza A::Subtipo H1N1 del Virus de la Influenza A [ORGANISMOS], Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics::Epidemiologic Studies::Cohort Studies [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], Técnicas de Investigación::Métodos Epidemiológicos::Características de Estudios Epidemiológicos::Estudios Epidemiológicos::Estudios de Cohortes [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Article, 03 medical and health sciences, SDG 3 - Good Health and Well-being, Adjuvants, Immunologic, Environmental health, Immunology and Microbiology(all), Influenza, Human, Other subheadings::Other subheadings::/adverse effects [Other subheadings], Humans, Adjuvants, H1N1 Subtype/immunology, Narcolepsy, Retrospective Studies, General Veterinary, General Immunology and Microbiology, Therapeutics::Biological Therapy::Immunomodulation::Immunotherapy::Immunization::Immunotherapy, Active::Vaccination [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES AND EQUIPMENT], business.industry, terapéutica::terapia biológica::inmunomodulación::inmunoterapia::inmunización::inmunoterapia activa::vacunación [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Environmental and Occupational Health, Public Health, Environmental and Occupational Health, Retrospective cohort study, Pandemic H1N1 influenza, medicine.disease, Adjuvants, Immunologic/therapeutic use, veterinary(all), Influenza, Viruses::RNA Viruses::Orthomyxoviridae::Influenzavirus A::Influenza A virus::Influenza A Virus, H1N1 Subtype [ORGANISMS], Case-Control Studies, business, 030217 neurology & neurosurgery
Abstract

Altres ajuts: This study was funded by the Centers for Disease Control and Prevention (CDC), Atlanta, USA, under CDC contract number 200-2012-53425_addendum 0001. This study was also supported by Public Health Ontario (PHO) and the Institute for Clinical Evaluative Sciences (ICES), which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). In 2010, a safety signal was detected for narcolepsy following vaccination with Pandemrix, an AS03-adjuvanted monovalent pandemic H1N1 influenza (pH1N1) vaccine. To further assess a possible association and inform policy on future use of adjuvants, we conducted a multi-country study of narcolepsy and adjuvanted pH1N1 vaccines. We used electronic health databases to conduct a dynamic retrospective cohort study to assess narcolepsy incidence rates (IR) before and during pH1N1 virus circulation, and after pH1N1 vaccination campaigns in Canada, Denmark, Spain, Sweden, Taiwan, the Netherlands, and the United Kingdom. Using a case-control study design, we evaluated the risk of narcolepsy following AS03- and MF59-adjuvanted pH1N1 vaccines in Argentina, Canada, Spain, Switzerland, Taiwan, and the Netherlands. In the Netherlands, we also conducted a case-coverage study in children born between 2004 and 2009. No changes in narcolepsy IRs were observed in any periods in single study sites except Sweden and Taiwan; in Taiwan incidence increased after wild-type pH1N1 virus circulation and in Sweden (a previously identified signaling country), incidence increased after the start of pH1N1 vaccination. No association was observed for Arepanrix-AS03 or Focetria-MF59 adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the case-control study nor for children born between 2004 and 2009 in the Netherlands case-coverage study for Pandemrix-AS03. Other than elevated narcolepsy IRs in the period after vaccination campaigns in Sweden, we did not find an association between AS03- or MF59-adjuvanted pH1N1 vaccines and narcolepsy in children or adults in the sites studied, although power to evaluate the AS03-adjuvanted Pandemrix brand vaccine was limited in our study.

Published
2018

40. Is preeclampsia associated with restless legs syndrome?

Author

Ulf Kallweit, Claudio L. Bassetti, Michael Linnebank, J. O. Ramirez, S. A. S. Cabrera, Hildegard Hidalgo, S. G. Cabrera, University of Zurich, and Kallweit, U

Subjects
Adult, Pediatrics, medicine.medical_specialty, Adolescent, Iron, Population, Excessive daytime sleepiness, 610 Medicine & health, Disorders of Excessive Somnolence, 2700 General Medicine, Hematocrit, Severity of Illness Index, Preeclampsia, Young Adult, Pre-Eclampsia, Pregnancy, Risk Factors, Restless Legs Syndrome, Peru, mental disorders, Prevalence, medicine, Humans, Restless legs syndrome, education, education.field_of_study, Anemia, Iron-Deficiency, medicine.diagnostic_test, business.industry, Incidence, Epworth Sleepiness Scale, General Medicine, Middle Aged, medicine.disease, 10040 Clinic for Neurology, Physical therapy, Female, medicine.symptom, Sleep, business, Body mass index
Abstract

Objective Restless legs syndrome (RLS) is a common neurologic disorder. Secondary RLS includes pregnancy and iron deficiency. Prevalence of RLS in pregnancy ranges from 11% to 27%. We aimed to assess the frequency and characteristics of RLS in pregnancy in a Peruvian population and to evaluate the possible pregnancy or delivery complications due to RLS. Methods We assessed 218 consecutive expectant mothers at the inpatient clinic of the Hospital San Bartolome in Lima, Peru. Assessment was performed by using the standard diagnostic criteria for RLS and by using a clinical and diagnostic interview. Questionnaires for RLS severity, idiopathic RLS (IRLS), and excessive daytime sleepiness (EDS) according to the Epworth sleepiness scale (ESS) were used. Blood examination was performed for hemoglobin and hematocrit. For comparison, RLS patients were matched for age and body mass index (BMI) with pregnant women without RLS. Results Out of 218 patients, 40 (18.4%) fulfilled diagnostic criteria for RLS. In RLS patients, prophylactic iron supplementation therapy during pregnancy was less frequently taken ( P =.02). Pregnant women with RLS had a higher ESS score than pregnant controls (10.6 +/− 3.1 vs 7.6. +/− 3.6; P P =.03). Conclusions In our study, RLS was frequent in pregnant Peruvian women, especially in those without prophylactic iron supplementation. RLS patients described more EDS. Preeclampsia was more common in RLS. Our study is the first study to indicate a possible association between RLS and preeclampsia.

Published
2013

41. Continuous positive airway pressure therapy is effective for migraines in sleep apnea syndrome

Author

Ulf Kallweit, Verena Uhl, Peter S. Sandor, Hildegard Hidalgo, University of Zurich, and Kallweit, U

Subjects
education.field_of_study, business.industry, medicine.medical_treatment, Cluster headache, Population, Sleep apnea, 610 Medicine & health, medicine.disease, 10040 Clinic for Neurology, nervous system diseases, respiratory tract diseases, Obstructive sleep apnea, 2728 Neurology (clinical), Migraine, Anesthesia, medicine, Neurology (clinical), Continuous positive airway pressure, Headaches, medicine.symptom, education, business, Prospective cohort study
Abstract

In migraine, the frequency of obstructive sleep apnea syndrome (OSAS) is comparable to the general population,1 whereas in cluster headache (CH), the prevalence is 60%–80%.2 In migraine pathophysiology, the release of inflammatory neuropeptides might play an important role and hypoxia might be a trigger.3 In OSAS, the activation of inflammatory pathways may be caused by intermittent hypoxia.4 Continuous positive airway pressure (CPAP) therapy improves morning headache in OSAS and seems to be effective in CH.2 There is little known on the effect of CPAP therapy on migraine in patients with OSAS. We hypothesized that migraine frequency would be decreased in patients with OSAS treated with CPAP, so we assessed the frequency and characteristics of migraine in OSAS and the effects of CPAP therapy on migraine. ### Classification of evidence. This study provides Class III evidence that CPAP given for 1 year to patients with migraine and OSAS significantly decreases the frequency of their migraine headaches. ### Methods. We prospectively studied a series of 107 consecutive inpatients with OSAS; those fulfilling diagnostic criteria5 for migraine were included in the study and assessed before and 1 year after treatment with CPAP. Sleep apnea was defined as apnea-hypopnea …

Published
2011

42. Efficiency of sodium oxybate in episodic cluster headache

Author

Verena Uhl, Andreas R. Gantenbein, Ulf Kallweit, Peter S. Sandor, Hildegard Hidalgo, University of Zurich, and Kallweit, U

Subjects
Male, Sodium Oxybate, business.industry, Cluster Headache, 610 Medicine & health, Middle Aged, 10040 Clinic for Neurology, Treatment Outcome, 2728 Neurology (clinical), Neurology, Episodic cluster headache, Anesthesia, 2808 Neurology, Medicine, Humans, Neurology (clinical), business, Adjuvants, Anesthesia
Abstract

We report the case of a 60-year-old man suffering from episodic cluster headache treated successfully with sodium oxybate. Sodium oxybate may be a therapeutic option in attacks of episodic cluster headache.

Published
2013

43. Elevated CSF histamine levels in multiple sclerosis patients

Author

Michael Linnebank, Kosuke Aritake, Stephan Blumenthal, Osamu Hayaishi, Yoshihiro Urade, Ulf Kallweit, Christian R. Baumann, Claudio L. Bassetti, University of Zurich, and Kallweit, U

Subjects
medicine.medical_specialty, Neurology, Central nervous system, 2804 Cellular and Molecular Neuroscience, Histamine receptors, CSF, 610 Medicine & health, Gastroenterology, Multiple sclerosis, 2806 Developmental Neuroscience, Cellular and Molecular Neuroscience, Histamine receptor, chemistry.chemical_compound, Cerebrospinal fluid, Developmental Neuroscience, Internal medicine, medicine, Short Paper, Receptor, Chronic inflammatory diseases, Granulocyte-macrophage colony-stimulating factor, Hematology, business.industry, General Medicine, medicine.disease, 10040 Clinic for Neurology, medicine.anatomical_structure, chemistry, 2808 Neurology, Immunology, business, Histamine
Abstract

BACKGROUND Histamine is an ubiquitous inflammatory mediator of numerous physiological processes. Histamine and its receptors have been implicated in multiple sclerosis (MS) disease pathogenesis. We prospectively enrolled 36 MS patients and 19 age and gender-matched healthy volunteers for cerebrospinal fluid (CSF) histamine analysis. FINDINGS CSF HISTAMINE LEVELS IN MS PATIENT SAMPLES WERE SIGNIFICANTLY HIGHER (MEDIAN: 35.6 pg/ml) than in controls (median: 5.5 pg/ml; Beta = 0.525, p

Published
2013

44. Association of restless legs syndrome, chronic motor tic disorder and migraine with aura: a case of a single family

Author

Sonja Tartarotti, Claudio L. Bassetti, Ulf Kallweit, University of Zurich, and Kallweit, U

Subjects
medicine.medical_specialty, Pediatrics, Neurology, Aura, 610 Medicine & health, Neurological disorder, medicine.disease, Migraine with aura, Surgery, 10040 Clinic for Neurology, Central nervous system disease, 2728 Neurology (clinical), Migraine, 2808 Neurology, medicine, Neurology (clinical), Restless legs syndrome, medicine.symptom, Psychology, Chronic motor tic disorder
Published
2010

45. Barriers to therapy adherence in narcolepsy.

Author

Finger BM, Bourke AM, Lammers GJ, Veauthier C, Yildizli M, Müller S, Triller A, and Kallweit U

Subjects
Humans, Female, Male, Adult, Surveys and Questionnaires, Middle Aged, Depression drug therapy, Narcolepsy drug therapy, Narcolepsy psychology, Medication Adherence psychology, Medication Adherence statistics & numerical data
Abstract

Background: Treatment adherence (TA) in narcolepsy is a complex phenomenon influenced by various factors beyond patient-related aspects. The management of narcolepsy involves non-pharmacological and symptomatic pharmacological treatment. Factors such as chronic daytime sleepiness, cognitive deficits, psychiatric comorbidities and adverse effects of pharmacological treatment are aspects of narcolepsy that could undermine TA, impacting patients' ability or willingness to consistently follow treatment plans. The aim of this study was to identify the factors influencing TA in narcolepsy and to determine the most significant barriers to adherence., Methods: An online survey was conducted during the pandemic, assessing demographic and clinical data, medication usage, and adverse effects of treatment. Various questionnaires, such as the Adherence Barriers Questionnaire (ABQ) and Epworth Sleepiness Scale (ESS), were utilized. The ABQ identified patient-specific barriers to medication adherence, while the Patient Health Questionnaire (PHQ-9) assessed depressive symptoms., Results: We analyzed 243 narcolepsy patients (77 % female, mean age 35.7 ± 12.3 years) with 71 % having narcolepsy type 1 (NT1). The average ESS score was 16.4 (SD ± 3.7). Adherence barriers (AB) were identified in 89 % of patients (216/243) based on ABQ score. The most common barriers reported were "Forgetfulness" (77 %), "Depression" (57 %), and "Side effect-driven medication reduction/stopping behavior" (49 %). Approximately 72 % of patients reported side effects from their narcolepsy medication, leading to discontinuation in 78 % of cases. A moderate correlation was found between the severity of adherence barriers (ABQ score) and levels of depression (PHQ-9 score; rs = 0.412, p = 00.000), as well as ESS score (p = . 048). The results of this study may have been influenced by the pandemic situation., Conclusion: Adherence barriers are common (89 %) and diverse among people with narcolepsy. Many barriers are related to excessive daytime sleepiness (EDS), cognitive deficits or depressive symptoms, highlighting the importance of recognizing and addressing them for optimal TA. Medication side effects, especially occurring when polypharmacology is utilized, also significantly contribute to adherence challenges. Effective communication regarding therapy adherence and improved detection and management of EDS and depression are crucial for enhancing TA in narcolepsy patients., Competing Interests: Declaration of competing interest The authors declare no potential conflicts of interest., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2024
Full Text
View/download PDF

46. Pharmacological management of narcolepsy in children and adolescents.

Author

Plazzi G, Pizza F, Lecendreux M, Gringras P, Barateau L, Bruni O, Franco P, Iranzo A, Jennum P, Khatami R, Knudsen-Heier S, Miano S, Nobili L, Partinen M, Reading P, Sonka K, Szakacs A, Zenti M, Kallweit U, Lammers GJ, Dauvilliers Y, and Bassetti CLA

Subjects
Humans, Adolescent, Child, Central Nervous System Stimulants therapeutic use, Central Nervous System Stimulants pharmacology, Narcolepsy drug therapy
Published
2024
Full Text
View/download PDF

48. A strategic neurological research agenda for Europe: Towards clinically relevant and patient-centred neurological research priorities.

Author

Boon P, Lescrauwaet E, Aleksovska K, Konti M, Berger T, Leonardi M, Marson T, Kallweit U, Moro E, Toscano A, Rektorova I, Crean M, Sander A, Joyce R, and Bassetti C

Subjects
Humans, Global Burden of Disease, Research, Europe epidemiology, Nervous System Diseases epidemiology, Nervous System Diseases therapy, Neurology
Abstract

Background and Purpose: Neurological disorders constitute a significant portion of the global disease burden, affecting >30% of the world's population. This prevalence poses a substantial threat to global health in the foreseeable future. A lack of awareness regarding this high burden of neurological diseases has led to their underrecognition, underappreciation, and insufficient funding. Establishing a strategic and comprehensive research agenda for brain-related studies is a crucial step towards aligning research objectives among all pertinent stakeholders and fostering greater societal awareness., Methods: A scoping literature review was undertaken by a working group from the European Academy of Neurology (EAN) to identify any existing research agendas relevant to neurology. Additionally, a specialized survey was conducted among all EAN scientific panels, including neurologists and patients, inquiring about their perspectives on the current research priorities and gaps in neurology., Results: The review revealed the absence of a unified, overarching brain research agenda. Existing research agendas predominantly focus on specialized topics within neurology, resulting in an imbalance in the number of agendas across subspecialties. The survey indicated a prioritization of neurological disorders and research gaps., Conclusions: Building upon the findings from the review and survey, key components for a strategic and comprehensive neurological research agenda in Europe were delineated. This research agenda serves as a valuable prioritization tool for neuroscientific researchers, as well as for clinicians, donors, and funding agencies in the field of neurology. It offers essential guidance for creating a roadmap for research and clinical advancement, ultimately leading to heightened awareness and reduced burden of neurological disorders., (© 2023 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.)

Published
2024
Full Text
View/download PDF

49. Role of sleep in neurodegeneration: the consensus report of the 5th Think Tank World Sleep Forum.

Author

Ferini-Strambi L, Liguori C, Lucey BP, Mander BA, Spira AP, Videnovic A, Baumann C, Franco O, Fernandes M, Gnarra O, Krack P, Manconi M, Noain D, Saxena S, Kallweit U, Randerath W, Trenkwalder C, Rosenzweig I, Iranzo A, Bradicich M, and Bassetti C

Subjects
Middle Aged, Animals, Humans, Aged, Sleep, Amyloid beta-Peptides cerebrospinal fluid, Sleep Apnea, Obstructive, REM Sleep Behavior Disorder, Alzheimer Disease, Neurodegenerative Diseases
Abstract

Sleep abnormalities may represent an independent risk factor for neurodegeneration. An international expert group convened in 2021 to discuss the state-of-the-science in this domain. The present article summarizes the presentations and discussions concerning the importance of a strategy for studying sleep- and circadian-related interventions for early detection and prevention of neurodegenerative diseases. An international expert group considered the current state of knowledge based on the most relevant publications in the previous 5 years; discussed the current challenges in the field of relationships among sleep, sleep disorders, and neurodegeneration; and identified future priorities. Sleep efficiency and slow wave activity during non-rapid eye movement (NREM) sleep are decreased in cognitively normal middle-aged and older adults with Alzheimer's disease (AD) pathology. Sleep deprivation increases amyloid-β (Aβ) concentrations in the interstitial fluid of experimental animal models and in cerebrospinal fluid in humans, while increased sleep decreases Aβ. Obstructive sleep apnea (OSA) is a risk factor for dementia. Studies indicate that positive airway pressure (PAP) treatment should be started in patients with mild cognitive impairment or AD and comorbid OSA. Identification of other measures of nocturnal hypoxia and sleep fragmentation could better clarify the role of OSA as a risk factor for neurodegeneration. Concerning REM sleep behavior disorder (RBD), it will be crucial to identify the subset of RBD patients who will convert to a specific neurodegenerative disorder. Circadian sleep-wake rhythm disorders (CSWRD) are strong predictors of caregiver stress and institutionalization, but the absence of recommendations or consensus statements must be considered. Future priorities include to develop and validate existing and novel comprehensive assessments of CSWRD in patients with/at risk for dementia. Strategies for studying sleep-circadian-related interventions for early detection/prevention of neurodegenerative diseases are required. CSWRD evaluation may help to identify additional biomarkers for phenotyping and personalizing treatment of neurodegeneration., (© 2023. Fondazione Società Italiana di Neurologia.)

Published
2024
Full Text
View/download PDF

50. Pitolisant-supported bridging during drug holidays to deal with tolerance to modafinil in patients with narcolepsy.

Author

Winter Y, Lang C, Kallweit U, Apel D, Fleischer V, Ellwardt E, and Groppa S

Subjects
Humans, Modafinil therapeutic use, Quality of Life, Piperidines adverse effects, Benzhydryl Compounds adverse effects, Narcolepsy drug therapy, Narcolepsy chemically induced, Disorders of Excessive Somnolence drug therapy
Abstract

Study Objectives: Modafinil is a common treatment for excessive daytime sleepiness (EDS) in narcolepsy. The long-term use of modafinil can lead to tolerance with the loss of efficacy and the continuous increase of its dose. Pharmacological strategies to deal with the tolerance to modafinil are lacking. We investigated the efficacy and safety of pitolisant-supported bridging during drug holidays in patients with tolerance to modafinil., Methods: Narcolepsy patients on monotherapy with modafinil who developed symptoms of tolerance were eligible. The following alternating therapy regimen was established: Monday to Friday patients continued on modafinil whereas Saturday and Sunday they switched to pitolisant to "bridge" the EDS symptoms. Patients were assessed at baseline and after three months with the Epworth Sleepiness Scale (ESS) and the Ullanlinna Narcolepsy Scale (UNS). Health-related quality of life (HrQol) was evaluated by EuroQol5D. Adverse events were documented in the patients' diaries., Results: 41 patients aged 30.9 ± 5.6 years were included. After three months of the alternating therapy regimen, the symptoms of tolerance decreased and the modafinil dose could be reduced by 41% (p < 0.01) resulting in better safety. The EDS improved on ESS (baseline: 18.2 ± 4.2, follow-up: 12.6 ± 4.0, p < 0.0001) and UNS (baseline: 25.8 ± 7.9, follow-up: 18.9 ± 5.9, p < 0.0001). The HrQol increased significantly., Conclusion: Patients with tolerance to modafinil could benefit from pitolisant-supported bridging during drug holidays. This alternating pharmacological strategy proved to be safe and helped to reduce EDS and to decrease the modafinil dose. Further randomized controlled studies are required to evaluate the different strategies to deal with the tolerance to modafinil., Clinical Trial Registration Number: Clinical Trials.gov Identifier NCT05321355., Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: YW reports honoraria for educational presentations and consultations from Angelini Pharma, Arvelle Therapeutics, Bayer AG, BIAL, Bioprojet, Bristol-Myers Squibb, JAZZ pharmaceuticals, Eisai, LivaNova, Novartis, Precisis and UCB Pharma. SG received compensation for professional services from Abbott, Abbvie, Bial, Medtronic, UCB and Zambon; research grants from Abbott, Boston Scientific, MagVenture, German Research Council and German Ministry of Education and Health. UK received honoraria for consulting from AOP Health, Bioprojet Pharma, Jazz Pharmaceuticals and Takeda Pharma. CL received honoraria for consulting and educational presentations from Bioprojet, UCB and Jazz Pharmaceuticals. Financial disclosure of VF, DA and EE: none. Non-financial disclosure of YW, SG, UK, CL, VF, DA and EE: none., (Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.)

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results